诺和诺德周一表示，已对在线远程医疗服务商 Hims & Hers 提起诉讼，指控其在美国大规模营销更便宜、未经批准的该公司新款减肥药 Wegovy 口服片和注射剂的仿制配制版本。诺和诺德请求法院永久禁止 Hims 销售侵犯其专利权的配制版药物，并寻求赔偿损失。诺和诺德在声明中指责 Hims “误导患者并将其健康置于风险之中”，因为这些仿制版本的安全性、有效性和质量均未经过美国监管机构的验证。 此举标志着诺和诺德与 Hims 之间的争端进一步升级。Hims 上周六表示，在面临联邦监管机构审查和这家丹麦制药商的法律威胁后，将停止提供其新款减肥口服药的仿制版本。Hims 原计划将该口服药首月售价定为最低49美元，比诺和诺德获批的 Wegovy 口服片价格低约100美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.